SBIR Phase I: Novel Breath Diagnostic Instrument for Detection of Disease

SBIR 第一阶段：用于检测疾病的新型呼吸诊断仪

• 批准号: 0214522
• 负责人: Douglas Baer
• 金额: $ 10万
• 依托单位: LOS GATOS RESEARCH INC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-07-01 至 2002-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0214522&HistoricalAwards=false
• 关键词: SBIR; Phase; Novel; Breath; Diagnostic

This Small Business Innovation Research (SBIR) Phase I project proposes to develop a carbon isotope ratio analyzer based on Off-Axis Integrated Cavity Output Spectroscopy to measure the ratio of C13 to C12 in exhaled breath in real time. The analyzer will serve as a medical diagnostic instrument that will operate in a point-of-care setting and reference labs. The instrument will be inexpensive, portable, easy-to-use and report C13/ C12 measurements with sufficient sensitivity and precision to replace mass spectrometry in C13-labeled breath tests for diagnosis of a number of conditions, including exposure to chemical and biological warfare agents, sepsis, assessment of liver and pancreatic function, delayed gastric emptying, bacterial overgrowth, irritable bowel syndrome and viral infection. The Phase I Project will develop an instrument to determine infection due to Helicobacter pylori, a Class-1 carcinogen, using the C13-urea breath test. The follow on Phase II Project will develop a prototype commercial instrument for clinical trials.The commercial application of this project is in the area of medical diagnostics.

本小企业创新研究（SBIR）一期项目拟开发基于离轴集成腔输出光谱的碳同位素比值分析仪，实时测量呼出气体中C13与C12的比值。该分析仪将作为一种医疗诊断仪器，在护理点环境和参考实验室中运行。该仪器价格低廉，便携，易于使用，具有足够的灵敏度和精度，可替代C13标记呼吸测试中的质谱法，用于诊断多种疾病，包括暴露于化学和生物战剂，败血症，肝脏和胰腺功能评估，胃排空延迟，细菌过度生长，肠易激综合征和病毒感染。一期项目将开发一种仪器，使用c13 -尿素呼气试验来确定幽门螺杆菌感染，幽门螺杆菌是一类致癌物。接下来的第二期计划将开发一种原型商业仪器用于临床试验。该项目的商业应用是在医疗诊断领域。